Molecular signatures of thyroid follicular neoplasia

Endocrine-Related Cancer

Volumn 17, Issue 3, 2010, Pages 691-708

  Borup, Rehannah ^a   Rossing, Maria ^a   Henao, Ricardo ^a   Yamamoto, Yohei ^a,e   Krogdahl, Annelise ^d   Godballe, Christian ^d   Winther, Ole ^a,f   Kiss, Katalin ^c   Christensen, Lise ^a   Høgdall, Estrid ^c   Bennedbæk, Finn ^b   Nielsen, Finn Cilius ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Departments of Endocrinology and Metabolism   (United States)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AKITA UNIVERSITY   (Japan)

^f TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; NUCLEAR RECEPTOR NR4A3; PROTEIN NR4A1; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GENETICS; CANCER GROWTH; CELL PROLIFERATION; DNA REPLICATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTORS, STEROID; RECEPTORS, THYROID HORMONE; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77956354810     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0288     Document Type: Article

References (64)

1. Ayllon V & O'connor R 2007 PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response. Oncogene 26 3451-3461.
2. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA & Fahey TJ III 2003 Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clinical Cancer Research 9 1792-1800.
3. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Marshall KA et al. 2009 NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Research 37 D885-D890.
4. Benjamini Y & Hochberg Y 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B 57 289-300.
5. Bolstad BM, Irizarry RA, Astrand M & Speed TP 2003 A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19 185-193.
6. Boukarabila H, Saurin AJ, Batsche E, Mossadegh N, van LM, Otte AP, Pradel J, Muchardt C, Sieweke M & Duprez E 2009 The PRC1 polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes and Development 23 1195-1206.
7. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E et al. 2008 Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS ONE 3 e3695.
8. Camacho CP, Latini FR, Oler G, Hojaij FC, Maciel RM, Riggins GJ & Cerutti JM 2009 Down-regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium treatment. Clinical Endocrinology 70 475-483.
9. Campone M, Campion L, Roche H, Gouraud W, Charbonnel C, Magrangeas F, Minvielle S, Geneve J, Martin AL, Bataille R et al. 2008 Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Research and Treatment 109 491-501.
10. Castro P, Sansonetty F, Soares P, Dias A & Sobrinho-Simoes M 2001 Fetal adenomas and minimally invasive follicular carcinomas of the thyroid frequently display a triploid or near triploid DNA pattern. Virchows Archiv 438 336-342. (Pubitemid 32285357)
11. Chen S, Fazle Akbar SM, Zhen Z, Luo Y, Deng L, Huang H, Chen L & Li W 2004 Analysis of the expression of Fas, FasL and Bcl-2 in the pathogenesis of autoimmune thyroid disorders. Cellular & Molecular Immunology 1 224-228.
12. Delellis RA 2006 Pathology and genetics of thyroid carcinoma. Journal of Surgical Oncology 94 662-669.
13. Evan GI & Vousden KH 2001 Proliferation, cell cycle and apoptosis in cancer. Nature 411 342-348. (Pubitemid 32467043)
14. Fagin JA & Mitsiades N 2008 Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Practice & Research. Clinical Endocrinology & Metabolism 22 955-969.
15. Finley DJ, Zhu B, Barden CB & Fahey TJ III 2004 Discrimination of benign and malignant thyroid nodules by molecular profiling. Annals of Surgery 240 425-436.
16. Foukakis T, Gusnanto A, Au AY, Hoog A, Lui WO, Larsson C, Wallin G & Zedenius J 2007 A PCR-based expression signature of malignancy in follicular thyroid tumors. Endocrine-Related Cancer 14 381-391. (Pubitemid 47242637)
17. Fryknas M, Wickenberg-Bolin U, Goransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Hoog A, Larsson C, Grimelius L et al. 2006 Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biology 27 211-220.
18. Fujarewicz K, Jarzab M, Eszlinger M, Krohn K, Paschke R, Oczko-Wojciechowska M, Wiench M, Kukulska A, Jarzab B & Swierniak A 2007 A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocrine-Related Cancer 14 809-826. (Pubitemid 350074069)
19. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J et al. 2004 Bioconductor: open software development for computational biology and bioinformatics. Genome Biology 5 R80.
20. Ghossein R 2009 Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin. Archives of Pathology & Laboratory Medicine 133 683-691.
21. Gray D, Jubb AM, Hogue D, Dowd P, Kljavin N, Yi S, Bai W, Frantz G, Zhang Z, Koeppen H et al. 2005 Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Research 65 9751-9761.
22. Griffith OL, Melck A, Jones SJ & Wiseman SM 2006 Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. Journal of Clinical Oncology 24 5043-5051. (Pubitemid 46631408)
23. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A, Bergthorsson JT, He H, Blondal T, Geller F, Jakobsdottir M et al. 2009 Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nature Genetics 41 460-464.
24. Hall PA, Todd CB, Hyland PL, McDade SS, Grabsch H, Dattani M, Hillan KJ & Russell SE 2005 The septin-binding protein anillin is overexpressed in diverse human tumors. Clinical Cancer Research 11 6780-6786. (Pubitemid 41428731)
25. Hayward DG & Fry AM 2006 Nek2 kinase in chromosome instability and cancer. Cancer Letters 237 155-166.
26. Hegedus L 2004 Clinical practice. The thyroid nodule. New England Journal of Medicine 351 1764-1771.
27. Hegedus L, Bonnema SJ & Bennedbaek FN 2003 Management of simple nodular goiter: current status and future perspectives. Endocrine Reviews 24 102-132.
28. Hinsch N, Frank M, Doring C, Vorlander C & Hansmann ML 2009 QPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study. BMC Cancer 9 93.
29. Hoffmann R, Seidl T & Dugas M 2002 Profound effect of normalization on detection of differentially expressed genes in oligonucleotide microarray data analysis. Genome Biology 3 RESEARCH0033.
30. Jonson L, Vikesaa J, Krogh A, Nielsen LK, Hansen T, Borup R, Johnsen AH, Christiansen J & Nielsen FC 2007 Molecular composition of IMP1 ribonucleoprotein granules. Molecular & Cellular Proteomics 6 798-811. (Pubitemid 46831932)
31. Li C & Wong WH 2001 Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. PNAS 98 31-36.
32. Li QX, Ke N, Sundaram R & Wong-Staal F 2006 NR4A1, 2, 3 - an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis. Histology and Histopathology 21 533-540.
33. Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, Peng SY, Lai PL & Hsu HC 2008 ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma. Clinical Cancer Research 14 4814-4820.
34. Lubitz CC, Gallagher LA, Finley DJ, Zhu B & Fahey TJ III 2005 Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery 138 1042-1048.
35. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR & Libutti SK 2004 Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Research 64 2898-2903. (Pubitemid 38500631)
36. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA & Stamenkovic I 2000 Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Research 60 4122-4129. (Pubitemid 30636594)
37. Mitsiades CS, Poulaki V & Mitsiades N 2003 The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer. Journal of Endocrinology 178 205-216. (Pubitemid 37063062)
38. Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z, Voutsinas G, Tseleni-Balafouta S & Mitsiades N 2006 Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clinical Cancer Research 12 3705-3712. (Pubitemid 44000250)
39. Moll UM, Marchenko N & Zhang XK 2006 p53 and Nur77/p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 25 4725-4743. (Pubitemid 44187622)
40. Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J & Conneely OM 2007 Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nature Medicine 13 730-735. (Pubitemid 46889752)
41. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, Kroll TG & Nikiforov YE 2003 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. Journal of Clinical Endocrinology and Metabolism 88 2318-2326. (Pubitemid 36549913)
42. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL & Pritchard KI 2009 Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. Journal of the National Cancer Institute 101 644-650.
43. Otsubo T, Iwaya K, Mukai Y, Mizokami Y, Serizawa H, Matsuoka T & Mukai K 2004 Involvement of Arp2/3 complex in the process of colorectal carcinogenesis. Modern Pathology 17 461-467. (Pubitemid 41646602)
44. Perez-Montiel MD & Suster S 2008 The spectrum of histologic changes in thyroid hyperplasia: a clinicopathologic study of 300 cases. Human Pathology 39 1080-1087.
45. Platt JC 1999 Probabilities for SV machines. Advances in Large Margin Classifiers, pp 61-74. MIT Press: Cambridge, MA, USA.
46. Ploner A, Miller LD, Hall P, Bergh J & Pawitan Y 2005 Correlation test to assess low-level processing of high-density oligonucleotide microarray data. BMC Bioinformatics 6 80. (Pubitemid 41357935)
47. Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB et al. 2008 Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clinical Cancer Research 14 3327-3337.
48. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F & Dhesy-Thind B 2008 HER-2 and topoisomerase II as predictors of response to chemotherapy. Journal of Clinical Oncology 26 736-744.
49. Ruggeri RM, Campenni A, Baldari S, Trimarchi F & Trovato M 2008 What is new on thyroid cancer biomarkers. Biomarker Insights 3 237-252.
50. Shedden K, Chen W, Kuick R, Ghosh D, Macdonald J, Cho KR, Giordano TJ, Gruber SB, Fearon ER, Taylor JM et al. 2005 Comparison of seven methods for producing Affymetrix expression scores based on false discovery rates in disease profiling data. BMC Bioinformatics 6 26. (Pubitemid 41357988)
51. Simon R 2006 A checklist for evaluating reports of expression profiling for treatment selection. Clinical Advances in Hematology and Oncology 4 219-224. (Pubitemid 43949858)
52. Simon R, Lam A, Li MC, Ngan M, Menenzes S & Zhao Y 2007 Analysis of gene expression data using BRB-Array tools. Cancer Informatics 2 11-17. (Pubitemid 47075796)
53. Sotiriou C & Pusztai L 2009 Gene-expression signatures in breast cancer. New England Journal of Medicine 360 790-800.
54. Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V et al. 2008 Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. British Journal of Cancer 98 1710-1715. (Pubitemid 351684679)
55. Stacey SN, Gudbjartsson DF, Sulem P, Bergthorsson JT, Kumar R, Thorleifsson G, Sigurdsson A, Jakobsdottir M, Sigurgeirsson B, Benediktsdottir KR et al. 2008 Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nature Genetics 40 1313-1318.
56. Szabo I, Adams C & Gulbins E 2004 Ion channels and membrane rafts in apoptosis. Pflügers Archiv 448 304-312.
57. Taniwaki M, Takano A, Ishikawa N, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y & Daigo Y 2007 Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clinical Cancer Research 13 6624-6631. (Pubitemid 350206797)
58. Thierry-Mieg D & Thierry-Mieg J 2006 AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biology 7 (Supplement 1) S12-S14.
59. Tusher VG, Tibshirani R & Chu G 2001 Significance analysis of microarrays applied to the ionizing radiation response. PNAS 98 5116-5121.
60. Utiger RD 2005 The multiplicity of thyroid nodules and carcinomas. New England Journal of Medicine 352 2376-2378.
61. Vapnik V 1998 Statistical Learning Theory. New York, NY, USA: Wiley-Interscience.
62. Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, Schuppert F, Broelsch CE, Ringel MD & Eng C 2005 Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. Journal of Clinical Endocrinology and Metabolism 90 2512-2521. (Pubitemid 40686285)
63. Yu SP & Choi DW 2000 Ions, cell volume, and apoptosis. PNAS 97 9360-9362.
64. Zhan Y, Du X, Chen H, Liu J, Zhao B, Huang D, Li G, Xu Q, Zhang M, Weimer BC et al. 2008 Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nature Chemical Biology 4 548-556.